Emerging retatrutide, a combined-action drug targeting both GLP-1 and GIP receptors, is generating considerable interest within the weight loss community. Early clinical research have shown substantial reductions in overall weight and advancements in health markers for patients with excess weight . Researchers believe this novel approach may rep… Read More